# IMA203

Source: https://onco.cc/drugs/ima203/  
OnCo record `ima203` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IMA203 is an experimental TCR-T cell therapy from Immatics US in phase 3 trials for melanoma, aimed at PRAME.

## Summary

IMA203 is a TCR-T cell therapy developed by Immatics US. Its target is PRAME (the sponsor names PRAME). The sponsor states: An autologous, genetically engineered T-cell receptor (TCR)-T cell therapy directed against PRAME-expressing tumour cells, given as a one-time infusion followed by adjunctive low-dose IL-2 therapy for up to 10 days. ClinicalTrials.gov describes the intervention as: one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06743126 (SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma), in melanoma. The largest, NCT06743126, plans to enrol 360 participants with primary completion expected 2028-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: anzutresgene autoleucel; anzu-cel
- Tags: pipeline; ctgov-ingest
- Modality: TCR-T cell therapy
- Mechanism: An autologous, genetically engineered T-cell receptor (TCR)-T cell therapy directed against PRAME-expressing tumour cells, given as a one-time infusion followed by adjunctive low-dose IL-2 therapy for up to 10 days.

## Sources

- ClinicalTrials.gov: trials of IMA203: https://clinicaltrials.gov/search?intr=IMA203
- Sponsor pipeline page: https://www.immatics.com/pipeline/

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [PRAME](https://onco.cc/targets/prame/)
- companies: [Immatics](https://onco.cc/companies/immatics/)
- trials: [SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma](https://onco.cc/trials/nct06743126/)

---
JSON: https://onco.cc/api/v1/entities/ima203.json